Small bowel ultrasound predicts response to infliximab in pediatric CD
Use of small bowel ultrasound (SBUS) is a feasible, noninvasive tool to measure early treatment response to infliximab in children with Crohn’s disease (CD), suggests a study. Moreover, the first parameter to change is bowel wall hyperaemia (BWH), not bowel wall thickness.
